Trastuzumab-Induced Cardiomyopathy
| Autor: | Rachel Barish, Emily Gates, Ana Barac |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Cardiac function curve medicine.medical_specialty medicine.medical_treatment Cardiomyopathy Breast Neoplasms 030204 cardiovascular system & hematology Global Health Targeted therapy 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Breast cancer Trastuzumab Internal medicine medicine Humans 030212 general & internal medicine skin and connective tissue diseases neoplasms Human Epidermal Growth Factor Receptor 2 Cardiotoxicity business.industry Incidence General Medicine medicine.disease Heart failure Female Cardiomyopathies Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Cardiology Clinics. 37:407-418 |
| ISSN: | 0733-8651 |
| Popis: | Trastuzumab targets the human epidermal growth factor receptor 2 (HER2). Its overexpression occurs in 25% of breast cancers and is associated with aggressive tumor characteristics and poor prognosis in absence of targeted therapy. Trastuzumab dramatically improves HER2-positive breast cancer outcomes; however, its clinical use is associated with left ventricular dysfunction and heart failure. Patients receiving trastuzumab or other HER2-targeted therapies undergo routine cardiac function assessment. Holding and/or stopping trastuzumab treatment in the setting of left ventricular dysfunction is recommended. This article summarizes the role of trastuzumab in cancer treatment, the mechanisms of trastuzumab-induced cardiotoxicity, recent clinical investigations, and current controversies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|